Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Alexion Receives Three New U.S. Patents for Soliris® (eculizumab), Extending Patent Protection Into 2027
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patents No. 9,732,149; 9,718,880; and 9,725,504, which are directed to the composition of matter of eculizumab (Soliris®), pharmaceutical formulations of eculizumab, and methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab, respectively, and which will expire in 2027. [ABSTRACT FROM PUBLISHER]
No Comments.